TY  - JOUR
A1  - Robin, Marie
A1  - de Wreede, Liesbeth C.
A1  - Wolschke, Christine
A1  - Schetelig, Johannes
A1  - Eikema, Diderik-Jan
A1  - Van Lint, Maria Teresa
A1  - Knelange, Nina Simone
A1  - Beelen, Dietrich
A1  - Brecht, Arne
A1  - Niederwieser, Dietger
A1  - Vitek, Antonin
A1  - Bethge, Wolfgang
A1  - Arnold, Renate
A1  - Finke, Jürgen
A1  - Volin, Liisa
A1  - Yakoub-Agha, Ibrahim
A1  - Nagler, Arnon
A1  - Poiré, Xavier
A1  - Einsele, Hermann
A1  - Chevallier, Patrice
A1  - Holler, Ernst
A1  - Ljungman, Per
A1  - Robinson, Stephen
A1  - Radujkovic, Alekxandar
A1  - McLornan, Donal
A1  - Chalandon, Yves
A1  - Kröger, Nicolaus
T1  - Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
JF  - Haematologica
N2  - Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged >= 65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.
KW  - Prognostic scoring system
KW  - Societe Francaise
KW  - Gruppo-italiano
KW  - European group
KW  - Late mortality
KW  - Midollo-Osseo
KW  - LATE DEATHS
KW  - Survival
KW  - Blood
KW  - Ruxolitinib
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226386
VL  - 104
IS  - 9
ER  - 
TY  - JOUR
A1  - Santoro, Nicole
A1  - Labopin, Myriam
A1  - Giannotti, Federica
A1  - Ehninger, Gerard
A1  - Niederwieser, Dietger
A1  - Brecht, Arne
A1  - Stelljes, Matthias
A1  - Kröger, Nicolaus
A1  - Einsele, Herman
A1  - Eder, Matthias
A1  - Hallek, Michael
A1  - Glass, Bertram
A1  - Finke, Jürgen
A1  - Ciceri, Fabio
A1  - Mohty, Mohamad
A1  - Ruggeri, Annalisa
A1  - Nagler, Arnon
T1  - Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
JF  - Journal of Hematology & Oncology
N2  - Background: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. Methods: We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients >= 60 years. Results: Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p < 10(-4)). Reduced intensity conditioning (RIC) was administrated to 73 and 77% of Haplo and MUD, respectively (p = 0.23). Stem cell source was the bone marrow (BM) in 52% of the Haplo and 6% of MUD (p < 10(-4)). Anti-thymocyte globulin (ATG) was most frequently used in MUD (p < 10(-4)) while post-Tx cyclophosphamide (PT-Cy) was given in 62% of Haplo. Engraftment was achieved in 90% of the Haplo vs 97% of MUD (p < 10(-4)). In multivariate analysis, no significant difference was found between Haplo and MUD for acute (a) graft versus host disease (GVHD) grade II-IV, relapse incidence (RI), non-relapse mortality (NRM), leukemia free survival (LFS), graft-versus-host-free-relapse free survival (GRFS), and overall survival (OS). Extensive chronic (c) GVHD was significantly higher for MUD as compared to Haplo (HR 2, p = 0.01, 95% CI 1.17-3.47). A propensity score analysis confirmed the higher risk of extensive cGVHD for MUD without differences for other outcomes. Conclusions: Allo-SCT from both Haplo and MUD are valid option for AML patients >= 60 years of age with similar results. Transplantation from MUD was associated with higher extensive cGVHD. Our findings suggest that Haplo is a suitable and attractive graft source for patients >= 60 with AML in need of allo-SCT.
KW  - MUD
KW  - Haploidentical
KW  - Allogeneic stem cell transplantation
KW  - Acute myeloid leukemia
KW  - Elderly
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227315
VL  - 11
ER  -